Stock price when the opinion was issued
Extremely challenged, though business continues to do well. One headwind is weight loss drug success makes investors concerned that respiratory issues will go away. That won't happen. Advertising practices under scrutiny, and there could be a fine.
Numbers continue to grow. Valuation lower than historically.
CEO is a really good operator, but stock just doesn't seem to get any love. Numbers have been OK, but not any really great growth. Looks good on EBITDA (due to equipment depreciation), but not on earnings. Takeout rumours always swirl but he won't buy on that basis alone, praying for a takout, if the fundamentals aren't there.
The trend of keeping people out of hospitals sounds good, but he's a numbers guy and it doesn't have the growth he wants.
Continues to execute really well both organically and by acquisition. Sold off recently on management missteps on financing. Very attractive valuation, about 1/2 that of peers. Too cheap with the growth rate. No dividend.
(Analysts’ price target is $14.35)